Market Newsdesk

November 12, 2020 8:03 am

ManTech Acquires Minerva Engineering to Expand Full-spectrum Cyber Capabilities

HERNDON, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) — ManTech International Corporation (Nasdaq: MANT) has completed the acquisition of Minerva Engineering, a leading provider of advanced cyber solutions. Headquartered in Hanover, Maryland, and founded in 1997, Minerva Engineering offers a range of advanced cyber services that support the intelligence community (IC), including risk and vulnerability assessment, incident response and cyber intrusion detection, and wireless signal discovery.

This acquisition enhances and expands ManTech’s cyber defense capabilities within the IC, adding new customers, new past performance qualifications as well as mission-critical contracts. Furthermore, Minerva Engineering’s highly skilled and cleared professionals increase ManTech’s deep cybersecurity talent base.

“ManTech has a well-established reputation as a leader of full-spectrum cyber capabilities. We are pleased to add Minerva Engineering’s talented people and significant customers into the ManTech family. The addition of Minerva Engineering is highly complementary and further builds upon our differentiated cyber offering, delivering more to our customers while positioning us for continued growth,” said Kevin M. Phillips, ManTech Chairman, CEO and President.

About ManTech

ManTech provides mission-focused technology solutions and services for U.S. defense, intelligence and federal civilian agencies. In business more than 50 years, we excel in full-spectrum cyber operations, data collection & analytics, enterprise IT, agile DevOps systems engineering and software application development solutions that support national and homeland security. Additional information about ManTech can be found at mantech.com.

Forward-Looking Information

Statements and assumptions made in this press release, which do not address historical facts, constitute “forward-looking” statements that ManTech believes to be within the definition in the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties, many of which are outside of our control. Words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” or “estimate,” or the negative of these terms or words of similar import, are intended to identify forward-looking statements.

These forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes we anticipate. Factors that could cause actual results to differ materially from the results we anticipate include, but are not limited to, the following: failure to maintain our relationship with the U.S. government, or compete effectively for contract awards; inability to recruit and retain sufficient number of employees with specialized skill sets or necessary security clearances who are in great demand and limited supply; adverse changes in U.S. government spending for programs we support,
whether due to changing mission priorities, socio-economic policies, cost reduction initiatives by our customers, or other federal budget constraints generally; disruption of our business or damage to our reputation resulting from security breaches in customer systems, internal systems (including as a result of cyber or other security threats), or employee misconduct; failure to realize the full amount of our backlog or adverse changes in the timing of receipt of revenues under contracts included in backlog; issues relating to competing effectively for awards procured through the competitive bidding process; failure to obtain option awards, task orders or funding under contracts; renegotiation, modification or termination of our contracts, or failure to perform in conformity with contract terms or our expectations; failure to successfully integrate acquired companies or businesses into our operations or to realize any accretive or synergistic effects from such acquisitions; non-compliance with, or adverse changes in, complex U.S. government laws, procurement regulations or processes; and adverse results of U.S. government audits or other investigations of our government contracts. These and other risk factors are more fully discussed in the section entitled “Risk Factors” in ManTech’s Annual Report on Form 10-K previously filed with the Securities and Exchange Commission on Feb. 2
1
, 20
20
, Item 1A of Part II of our Quarterly Reports on Form 10-Q, and, from time to time, in ManTech’s other filings with the Securities and Exchange Commission.

The forward-looking statements included herein are only made as of the date of this press release, and ManTech undertakes no obligation to publicly update any of the forward-looking statements made herein, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Media Contact:

Jim Crawford
Executive Director, External Communications
(M) 571.446.7550
[email protected]

Investor Relations Contact:

Stephen Vather
VP, M&A and Investor Relations
703.218.6093
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/96b71004-78b3-4916-9dc2-f8b4fdb9bfd9

November 12, 2020 8:03 am

DIGITAL ALLY, INC ANNOUNCES THIRD QUARTER 2020 OPERATING RESULTS

Company reports 23% revenue increase and earnings per share of $.02 for the third quarter 2020

LENEXA, Kansas, Nov. 12, 2020 (GLOBE NEWSWIRE) — Digital Ally, Inc. (Nasdaq: DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, today announced its third quarter 2020 operating results. An investor conference call is scheduled for 11:15 p.m. EDT on Thursday, November 12, 2020 (see details below).

Highlights for the Third quarter Ended September 30, 2020

●	Total revenues increased 23% in the third quarter 2020 to $3,588,640 from $2,923,148 in the comparable 2019 period. Total revenues for the third quarter 2020 represent the highest quarterly revenue amount reported by the Company since the first quarter of 2017. The overall revenue increase is attributable to approximately $1.1 million of revenues generated by the Company’s new ThermoVU™ and Shield™ product lines during the third quarter 2020.

●	Our third quarter 2020 basic and diluted earnings per share was $0.02 representing a significant improvement from the net loss per share of ($0.26) reported in the comparable quarter in 2019. The improvement is primarily attributable to the 23% increase in total revenues, the 12% decrease in selling, general and administrative expenses and the $2,365,000 gain reported from the termination and extinguishment of the PIA obligation during the third quarter 2020 as compared to the similar period in 2019. Our earnings per share of $.02 represents for the third quarter 2020 represent our highest earnings per share amount reported by the Company since the first quarter of 2013.

●	The Company recently added two new lines of branded products: (1) the ThermoVu™ which is a line of self-contained temperature monitoring systems that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) our Shield™ disinfectants and cleansers which are for use against viruses and bacteria. We began offering such products beginning late in the second quarter 2020 and experienced strong demand during the third quarter resulting in total revenues for the quarter approximating $1.1 million. Shield™ disinfectants has been listed on the United States Environmental Protection Agency’s List N: Disinfectants for Use Against SARS-CoV-2, the virus that causes COVID-19. We expect continued revenue growth from these two new product lines in future quarters and are considering additional products to complement these new safety product lines. We are ramping up our supply chain for both of these new product lines, which are manufactured by third-parties. These branded products are being offered to our first responder customers including police, fire and paramedics. Commercial customers such as schools, cruise lines, taxi-cab and para transit are also be good candidates for the products, which the Company is actively pursuing.

●	The Covid-19 pandemic continued to delay the shipment of some orders in the third quarter 2020 as police forces and governments reacted to its impact. In general, our salesmen were unable to travel and meet with potential customers as they normally do to demonstrate our hardware, to promote our integrated solutions and close hardware sales. Specifically, we were unable to ship the initial purchase orders under a substantial contract awarded by the Director of Strategic Procurement of a country for the expected deployment of body cameras to its entire national police force. The contract was expected to include up to 5,000 body cameras with our web-based software infrastructure service over a three-year period. Contract deliveries were suspended pending the government’s decision to freeze the planned deployment until such time as the pandemic is contained within its population. The initial purchase order was expected to ship during the first quarter 2020 with follow-on orders for the second and third quarters of 2020 and would have made a substantial impact to our product revenues for the third quarter of 2020. At this point, we are unable to forecast if and when this major project will be restarted or how it may be modified as a result of the pandemic. Upon completion, the original contract would have been the largest body camera deployment in our history and the largest contract for recurring service revenues for our web-based software related to the body cameras.

●	The Company recorded a gain of $2,365,000 during the third quarter 2020 resulting from the termination and extinguishment of all obligations related to the Proceeds Investment Agreement (the “PIA”). On July 20, 2020, the Company and the holder of the PIA executed a Termination Agreement and Mutual Release (the “Termination Agreement”). Upon payment of $1,250,000 by the Company both parties agreed to terminate the PIA and to release each other from any further liability thereunder. In addition, the Company further agreed to pay the following: (a) a contingent payment in the amount of $2,750,000 following the closing of an asset purchase, membership interest purchase, or similar transaction between the Company and a specified third-party (the “Purchase Transaction”) and (b) any and all future proceeds received from Watchguard and its successors and assigns by the Company for WatchGuard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452. For clarity, the parties further agreed that the payment of the contingent payment would only be due and payable upon the closing of the specified Purchase Transaction and would automatically terminate if the specified Purchase Transaction was abandoned prior to its closing. The Company abandoned the Purchase Transaction during the third quarter 2020 and therefore, the contingent payment obligation automatically terminated. The Company recorded a as the specified Purchase Transaction was abandoned prior to its closing. Furthermore, the Company does not anticipate any future recoveries from Watchguard and its successors and assigns relative to WatchGuard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452.

●	On July 2, 2020 the SEC declared the Company’s shelf registration statement on Form S-3 effective. The Shelf Registration Statement will provide the Company with access to liquidity from the public markets should it decide to utilize it for such purposes. The Shelf Registration Statement allows the Company to offer and sell, from time to time in one or more offerings, any combination of our common stock, debt securities, debt securities convertible into Common Stock or other securities in any combination thereof, rights to purchase shares of Common Stock or other securities in any combination thereof, warrants to purchase shares of Common Stock or other securities in any combination thereof or units consisting of Common Stock or other securities in any combination thereof having an aggregate initial offering price not exceeding $125,000,000.

●	On August 21, 2020, the Company completed the purchase of a building which will serve as the company’s warehouse and distribution location for its new branded temperature screening device ThermoVU™ and its Shield™ line of disinfectant/cleanser products. The total purchase price was $420,000 and the Company used its available cash to close the building purchase.

●	We have asserted two significant patent infringement lawsuit involving Axon and WatchGuard that have had significant impacts on our quarterly results primarily due to the timing and amount of legal fees expended on such lawsuits. We settled the WatchGuard lawsuit in May 2019 for a total payment from WatchGuard of $6.0 million. In June 2019 the District Court granted Axon’s Motion for Summary Judgment, and accepted Axon’s position that it did not infringe on our patents and dismissed the lawsuit. We appealed the District Court’s ruling. On April 22, 2020, a three-judge panel of the United States Court of Appeals denied our appeal and affirmed the District Court’s previous decision to grant Axon summary judgment. On May 22, 2020, we filed a petition for panel rehearing requesting that we be granted a rehearing of our appeal of the U.S. District Court’s summary judgment ruling. Furthermore, we requested that we be given an opportunity to make our case through oral argument in front of the three-judge panel of the Court of Appeals, all of which was denied. The Company has abandoned its right to any further appeals and this matter is now concluded. Our litigation costs related to the Axon and other lawsuits has declined substantially in 2020 compared to 2019 and previous years. Furthermore, we believe our future quarterly results during the remainder of 2020 and beyond will continue to be positively impacted form the conclusion of these legal matters..

●	Our overall gross margin percentage declined to 34.1% in the third quarter 2020 compared to 40.7% in the 2019 period. The deterioration is attributable to the manufacturing inefficiencies and unfavorable overhead variances caused by the Covid-19 pandemic. We also continued to experience significant disruptions in the third quarter 2020 because we moved our office, manufacturing and warehouse facility to a newer and smaller location during June 2020.

●	Selling, general and administrative expenses were $3,066,606 and $3,468,709 for the third quarter 2020 and 2019, respectively, a decrease of $402,103 (12%). The significant decrease was the result of lower litigation costs due to the Company abandoning the Axon patent infringement lawsuit, sales and support staff headcount reductions due to the COVID-19 pandemic and we reduced overall travel in response to the impact of the Covid-19 pandemic during the third quarter 2020.

●	The COVID-19 pandemic represents a fluid situation that presents a wide range of potential impacts of varying durations for different global geographies, including locations where we have offices, employees, customers, vendors and other suppliers and business partners. Like most US-based businesses, the COVID-19 pandemic and efforts to mitigate the same began to have impacts on our business in March 2020. By that time, much of our first fiscal quarter was completed. During the quarter ended September 30, 2020, we have observed recent decreases in demand from certain customers, including primarily our law-enforcement and commercial customers. Given the fact that our products are sold through a variety of distribution channels, we expect our sales will experience more volatility as a result of the changing and less predictable operational needs of many customers as a result of the COVID-19 pandemic. We are aware that many companies, including many of our suppliers and customers, are reporting or predicting negative impacts from COVID-19 on future operating results. Although we observed significant declines in demand for our products from certain customers during the three months ended September 30, 2020, we believe that it remains too early for us to know the exact impact COVID-19 will have on the long-term demand for our products. We also cannot be certain how demand may shift over time as the impacts of the COVID-19 pandemic may go through several phases of varying severity and duration. To date, travel restrictions and border closures have not materially impacted our ability to obtain inventory or manufacture or deliver products or services to customers. However, if such restrictions become more severe, they could negatively impact those activities in a way that would harm our business over the long term. Travel restrictions impacting people can restrain our ability to assist our customers and distributors as well as impact our ability to develop new distribution channels, but at present we do not expect these restrictions on personal travel to be material to our business operations or financial results. We have taken steps to restrain and monitor our operating expenses and therefore we do not expect any such impacts to materially change the relationship between costs and revenues. Like most companies, we have taken a range of actions with respect to how we operate to assure we comply with government restrictions and guidelines as well as best practices to protect the health and well-being of our employees and our ability to continue operating our business effectively. To date, we have been able to operate our business effectively using these measures and to maintain all internal controls as documented and posted. We also have not experienced challenges in maintaining business continuity and do not expect to incur material expenditures to do so. However, the impacts of COVID-19 and efforts to mitigate the same have remained unpredictable and it remains possible that challenges may arise in the future.

Management Comments

Stanton E. Ross, Chief Executive Officer of Digital Ally, stated, “We are very pleased to report a 23% increase in total revenues for our third quarter and net earnings per share of $0.02. Furthermore, our third quarter 2020 total revenues of $3,588,640 represents our highest quarterly total for revenues since the first quarter of 2017 and our earnings per share represents our highest earnings per share since the first quarter of 2013. Our decision not to stand still during the Covid-19 pandemic and proactively expand our product offerings to include the ThermoVU and Shield lines has proven to be successful as they generated approximately $1.1 million in combined revenues during the third quarter 2020. We are considering further expansion of the ThermoVU and Shield product lines to include complementary products that we hope they will achieve similar market acceptance. We also reduced our SG&A expenses by reducing staffing levels, limiting travel and reducing many advertising and promotional activities. In addition, we moved to a new, smaller office and warehouse space in June 2020 that will dramatically reduce our occupancy costs for the balance of 2020 and beyond” concluded Ross.

Investor Conference Call

The Company will host an investor conference call at 11:15 p.m. EDT on Thursday, November 12, 2020, to discuss its operating results for the third quarter 2020, developments related to its disinfectant and safety products, the impact of the Covid-19 pandemic and other topics of interest. Shareholders and other interested parties may participate in the conference call by dialing 844-761-0863 and entering conference ID# 5148159 a few minutes before 11:15 p.m. EDT on Thursday November 12, 2020.

A replay of the conference call will be available two hours after its completion, from November 12, 2020 until 11:59 p.m. on January 12, 2021 by dialing 855-859-2056 and entering the conference ID # 5148159.

For additional news and information please visit or follow us on Twitter @digitalallyinc and Facebook www.facebook.com/DigitalAllyInc

Follow additional Digital Ally Inc. social media channels here:

Facebook
| Instagram | LinkedIn | Twitter

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: whether the Company will be able to improve its revenue and operating results, especially in light of the adverse effects of the Covid-19 pandemic on our customers, suppliers and employees; whether it will be able to resolve its liquidity and operational issues and raise sufficient capital given the impact of the Covid-19 pandemic; whether it will be able to achieve improved production and other efficiencies to restore its gross and operating margins in the future; whether the Company will be able to continue to expand into non-law enforcement markets, including disinfectant/sanitizer and temperature screening products, and increase its service based revenue; whether the Company has resolved its product quality and supply chain issues; whether the EVO-HD will help the Company increase its product revenues; whether the Company will continue to experience declines in legal expenses as a result of concluding its patent litigation; whether and the extent to which the US Patent and Trademark Office (USPTO) rulings will curtail, eliminate or otherwise have an effect on the actions of competitors and others in the marketplace respecting the Company, its products and customers; its ability to deliver its newer product offerings as scheduled, and in particular the new EVO-HD product platform, obtain the required components and products on a timely basis, and have them perform as planned; its ability to maintain or expand its share of the markets in which it competes, including those outside the law enforcement industry; whether it will be able to adapt its technology to new and different uses, including being able to introduce new products; competition from larger, more established companies with far greater economic and human resources; its ability to attract and retain customers and quality employees; the effect of changing economic conditions; and changes in government regulations, tax rates and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company’s disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “projects,” “should,” or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. It does not undertake to publicly update or revise forward-looking statements, whether because of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020 and in its annual report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (the “SEC”).

For Additional Information, Please Contact:

Stanton E. Ross, CEO, at (913) 814-7774 or

Thomas J. Heckman, CFO, at (913) 814-7774

(Financial Highlights Follow)

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2020 AND DECEMBER 31, 2019

	September 30, 2020 (Unaudited)			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	8,130,331		$	359,685
Accounts receivable-trade, less allowance for doubtful accounts of $123,224 – 2020 and 2019		1,799,935			1,071,018
Accounts receivable-other		884,853			514,730
Inventories, net		5,993,627			5,280,412
Income tax refund receivable, current		—			44,650
Prepaid expenses and other current assets		2,295,945			381,090

Total current assets		19,104,691			7,651,585

Land, building and equipment, net		681,315			197,063
Intangible assets, net		379,351			413,268
Operating lease right of use assets, net		792,121			122,459
Other assets		893,180			532,500

Total assets	$	21,850,658		$	8,916,875

Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$	1,058,739		$	2,339,985
Accrued expenses		616,343			845,881
Operating lease obligations – Current		83,094			159,160
Contract liabilities – Current		1,702,587			1,707,943
Debt obligations – Current		791,521			1,827,748
Income taxes payable		1,158			5,934
Total current liabilities		4,253,442			6,886,651

Long-term liabilities:
Proceeds investment agreement obligation, at fair value – Long-term		—			6,500,000
Operating lease obligation – Long-term		754,031			44,460
Debt obligations – Long-term		777,379			—
Contract liabilities – Long-term		1,663,481			1,803,143

Total liabilities		7,448,333			15,234,254

Commitments and contingencies

Stockholders’ Equity (Deficit):
Common stock, $0.001 par value per share; 100,000,000 and 50,000,000 shares authorized, respectively; shares issued: 26,836,209 – September 30, 2020 and 12,079,095 – December 31, 2019		26,836			12,079
Additional paid in capital		106,225,896			83,216,387
Treasury stock, at cost (63,518 shares)		(2,157,226	)		(2,157,226	)
Accumulated deficit		(89,693,181	)		(87,388,619	)

Total stockholders’ equity (deficit)		14,402,325			(6,317,379	)

Total liabilities and stockholders’ equity (deficit)	$	21,850,658		$	8,916,875

(FOR ADDITIONAL INFORMATION, PLEASE REFER TO THE COMPANY’S QUARTERLY REPORT ON FORM 10-Q FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 FILED WITH THE SEC)

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED

SEPTEMBER 30, 2020 AND 2019

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2020			2019			2020			2019

Revenue:
Product	$	2,958,579		$	2,173,257		$	5,778,695		$	6,039,445
Service and other		630,061			749,891			1,967,881			1,981,482

Total revenue		3,588,640			2,923,148			7,746,576			8,020,927

Cost of revenue:
Product		2,177,676			1,601,913			4,332,450			4,333,812
Service and other		188,316			132,973			533,690			366,301

Total cost of revenue		2,365,992			1,734,886			4,866,140			4,700,113

Gross profit		1,222,648			1,118,262			2,880,436			3,320,814
Selling, general and administrative expenses:
Research and development expense		405,083			517,010			1,250,528			1,562,086
Selling, advertising and promotional expense		789,854			877,218			1,958,884			2,871,154
General and administrative expense		1,871,668			2,074,481			5,585,500			7,686,537
Patent litigation settlement		—			—			—			(6,000,000	)

Total selling, general and administrative expenses		3,066,605			3,468,709			8,794,912			6,119,777

Operating loss		(1,843,957	)		(2,280,447	)		(5,914,476	)		(2,798,963	)

Other income (expense):
Interest income		11,339			6,667			33,208			30,279
Interest expense		(4,940	)		(37,037	)		(338,136	)		(37,037	)
Secured convertible notes issuance expense		—			(89,148	)		(34,906	)		(89,148	)
Change in fair value of proceeds investment agreement		2,365,000			(177,000	)		5,250,000			(3,275,000	)
Change in fair value of secured convertible notes		—			(408,860	)		(1,300,252	)		(408,860	)
Total other income (expense)		2,371,399			(705,378	)		3,609,914			(3,779,766	)

Income (loss) before income tax benefit		527,442			(2,985,825	)		(2,304,562	)		(6,578,729	)
Income tax benefit (expense)		—			—			—			—

Net income (loss)	$	527,442		$	(2,985,825	)	$	(2,304,562	)	$	(6,578,729	)

Net income (loss) per share information:
Basic	$	0.02		$	(0.26	)	$	(0.12	)	$	(0.58	)
Diluted	$	0.02		$	(0.26	)	$	(0.12	)	$	(0.58	)

Weighted average shares outstanding:
Basic		26,613,109			11,637,289			19,861,694			11,296,999
Diluted		26,627,941			11,637,289			19,861,694			11,296,999

(FOR ADDITIONAL INFORMATION, PLEASE REFER TO THE COMPANY’S QUARTERLY REPORT ON FORM 10-Q FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 FILED WITH THE SEC)

November 12, 2020 8:03 am

Dymax MD® 1172-M-UR Medical Device Adhesive for Difficult-to-Bond COC/COP Substrates

Features Ultra-Red® Fluorescing for High-Speed Automated Quality Inspection

TORRINGTON, Conn., Nov. 12, 2020 (GLOBE NEWSWIRE) — Dymax Corporation introduces MD^® 1172-M-UR, an LED UV and broad-spectrum light-curable adhesive for bonding COC/COP film laminates and other difficult-to-bond-to plastics used in the assembly of in-vitro diagnostics (IVD), Lab-on-a-chip (LOC), and other point-of-care medical devices. The product may also be of interest to manufacturers involved with the design of COVID-19 rapid diagnostic applications.

The adhesive is moisture resistant, soft and flexible with a durometer of A70, and has a viscosity of 1,100 cP for improved wetting. 1172-M-UR is formulated with Dymax Ultra-Red^® fluorescing technology for simple visual post-cure quality inspection of the bond line area. After cure, when exposed to low-intensity black light (365 nm), the material fluoresces bright red, making it easy to see on plastics that naturally fluoresce blue in color, like PVC. This ISO 10993-5 Cytotoxicity approved product is ideally suited for rapid diagnostic applications, microfluidics, reservoir and transducer assembly, and medical potting applications.

The product is LED optimized to cure in seconds upon exposure to LED UV (365 nm) or broad-spectrum light energy. By using this product in conjunction with a Dymax LED light-curing system, optimal cure time can be achieved, providing users with significant advantages over conventional lamp-curing systems including cooler curing temperatures, more consistent cure results, and lower intensity degradation over time.

About Dymax Corporation

Dymax Corporation develops innovative oligomer, adhesive, coating, dispensing, and rapid light-cure systems for applications in a wide range of markets. The company’s products are perfectly matched to work seamlessly with each other, providing design engineers with tools to dramatically improve manufacturing efficiency and reduce costs. Major markets include aerospace and defense; medical device; consumer and automotive electronics.

For additional information on Dymax, visit www.dymax.com or contact us at 860-482-1010.

Contact:                
Beth Schivley
Global Director Marketing Communications
Dymax Corporation
[email protected]

November 12, 2020 8:03 am

Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has entered into definitive agreements with several institutional and accredited investors, for the purchase and sale of 2,522,784 shares of its common stock, at a purchase price of $1.78375 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Histogen also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,892,088 shares of its common stock. The closing of the offering is expected to occur on or about November 16, 2020, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants have an exercise price of $ 1.70 per share, will be exercisable immediately upon issuance and will expire five and one-half years from the date of issuance.

The gross proceeds from this offering are expected to be approximately $4.5 million, before deducting placement agent’s fees and other offering expenses. Histogen intends to use the net proceeds from this offering for working capital and general corporate purposes, including expenses related to the clinical development of its products for its CCM, hECM and HSC programs, further research and development, capital expenditures and general and administrative expenses.

The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) are being offered by Histogen pursuant to a “shelf” registration statement on Form S-3 (File No. 333-248074) previously filed with the Securities and Exchange Commission (the “SEC”) on August 17, 2020 and declared effective by the SEC on August 26, 2020. The offering of the shares of common stock will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at [email protected].

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Histogen

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss our ability to satisfy the closing conditions of the offering and the timing of the closing, the use of proceeds, our future operations and our ability to successfully initiate and complete clinical trials, obtain clinical trial data, and achieve regulatory milestones and related timing, including those related to the submission of a HST-003 IND for regeneration of cartilage in the knee, any initiation of a HST-002 Phase 1 trial for the treatment of moderate to severe nasolabial folds and the reporting of topline data for the ongoing HST-001 Phase 1a/2b trial for androgenic alopecia in men and the planned Phase 1 study of emricasan for the treatment of COVID-19; the nature, strategy and focus of our business; the sufficiency of our cash resources and ability to achieve value for our stockholders; and the development and commercial potential and potential benefits of any of our product candidates, such as HST-001, HST-002 and HST-003. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of ours that could differ materially from those described in or implied by the statements in this press release, including: market and other conditions, the uncertainties associated with the clinical development and regulatory approval of our product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies of our product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase its costs and expenses; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in our filings with the Securities and Exchange Commission. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

Contact:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
[email protected]

November 12, 2020 8:03 am

Westwater Resources Announces Third Quarter 2020 Results and Business Update

Westwater Resources Announces Third Quarter 2020 Results and Business Update

Company Will Update Investors on Its Coosa Graphite Project and Ongoing Construction of Pilot Plant in Germany

CENTENNIAL, Colo.–(BUSINESS WIRE)–Westwater Resources (NASDAQ: WWR), an energy materials development company, today announced its results for the third quarter ended September 30, 2020 and provided an update on its materials development business.

Founded four decades ago and originally incorporated to mine uranium, Westwater Resources has been reinvented as a 21^st century energy materials development company focused on the production of battery-grade graphite. The Company’s Coosa Graphite Project is the most advanced graphite project in the United States and, when developed, will produce high purity battery-grade graphite, a material that is essential for the components of high-technology energy applications such as electric automobiles.

Westwater recently announced delivery of 30 metric tonnes of natural flake graphite concentrate at pilot plant contractor Dorfner Anzaplan’s facility in Hirschau, Germany. This material is being utilized in the Company’s pilot plant facilities presently under construction in Germany, upstate New York and Illinois. Operation of the pilot plants is expected to commence this month and continue through March 2021.

Westwater continues to develop a proprietary process for the production of non-Chinese battery-grade graphite. The Company has filed a provisional patent application with the U.S. Patent and Trademark Office for its proprietary graphite purification technology, which produces battery-grade graphite with a more sustainable environmental footprint than that produced in China. Independent performance testing of Westwater’s ULTRA-CSPG™ (Coated Spherical Purified Graphite or “CSPG”) material produced in a laboratory setting shows that it performs as well or better than benchmark commercially available natural flake and synthetic materials. Independent performance testing of Westwater’s ULTRA-PMG™ (Purified Micronized Graphite or “PMG”) material has also shown outstanding resistivity values as a conductivity enhancer.

During the third quarter, Westwater added to its management team by appointing Jay Wago as Vice President of Sales and Marketing. Mr. Wago has years of solid experience in the battery materials business, and he has been tasked with bolstering the Company’s marketing strategy to create greater awareness of Westwater’s American-made graphite battery material to end-users worldwide. The Westwater marketing team, under Mr. Wago’s direction, is working to place battery-grade graphite products produced during the pilot plant program in the hands of potential customers.

On September 8, 2020, Westwater entered into a Letter of Intent to sell its U.S. uranium business to enCore Energy Corp. of Vancouver, BC, a Toronto Venture Exchange-listed company (TSX.V:EU). Westwater will receive approximately $2 million in shares of enCore stock and will retain royalty interests on its former New Mexico properties. This sale is expected to eliminate approximately $4 million in annual expenditures by the Company and nearly $7.8 million in liabilities based on September 30, 2020 book values. The transaction is expected to close on or before December 31, 2020. Westwater will retain its interests in its uranium business that is the subject of an international arbitration with the Republic of Turkey.

On September 30, 2020, the U.S. President issued an executive order addressing the threat to the United States domestic supply chain of reliance on critical minerals from foreign adversaries and declaring such reliance a national emergency. The critical minerals referred to in the executive order were previously identified by the Department of Interior in May 2018, and include both natural graphite and vanadium. The executive order highlights the importance of Westwater’s plans to develop the Coosa Graphite Deposit in east-central Alabama, where the Company has also discovered widespread and significant levels of vanadium mineralization. In 2021, Westwater expects to commence further exploration for vanadium at the Coosa Graphite Project.

“Our management team possesses a unique combination of battery materials knowledge and extensive project-execution experience alongside manufacturing and processing expertise. This expertise spans everything from graphite to precious metals to energy materials,” said Chris Jones, CEO of Westwater Resources. “Coupled with decades of capital markets experience, we have what we need to build a powerful presence in the new energy marketplace. In the third quarter of 2020 we reached a number of significant milestones, and I believe these milestones position our Company for growth throughout 2021. We continue to execute our business plan without pause.”

FINANCIAL SUMMARY

Table 1: Financial Summary

(000’s, Except Per Share)	3Q 2020	3Q 2019	3Q Variance	9-Mos 2020	9-Mos 2019		9-Mos Variance
Net Cash Used in Consolidated Operations	$ (4,069)	$ (2,868)	42%	$ (10,134)	$ (7,192)	41%
Product Development Expenses	$ (1,641)	$ (19)	n/m	$ (1,942)	$ (51)	n/m
General and Administrative	$ (1,536)	$ (1,003)	53%	$ (4,106)	$ (3,583)	15%
Net Loss from Continuing Operations	$ (3,362)	$ (1,170)	187%	$ (6,932)	$ (4,731)	47%
Net Loss from Discontinued Operations	$ (6,389)	$ (664)	862%	$ (8,573)	$ (3,052)	181%
Net Loss	$ (9,751)	$ (1,834)	432%	$ (15,505)	$ (7,783)	99%
Net Loss Per Share	$ (1.23)	$ (0.95)	29%	$ (2.63)	$ (4.66)	-43%
Weighted Avg. Shares Outstanding	7,905	1,931	309%	5,906	1,649	258%

Net Cash Used in Consolidated Operations. Net cash used in all operating activities was $10.1 million for the nine months ended September 30, 2020, as compared with $7.2 million for the same period in 2019. The $2.9 million increase in cash used in operating activities was primarily due to increased graphite product development expenses, general and administrative expenses and arbitration costs in 2020 compared to 2019. The increase of $1.2 million in cash used during the three-months ended September 30, 2020 compared to the prior year three-month period was primarily due to expenditures for graphite product development activities.
Product Development Expenses. For the three and nine months ended September 30, 2020, product development expenses from continuing operations increased by $1.6 million and $1.9 million, respectively, from the corresponding periods in 2019. Management’s decision to discontinue uranium and lithium operations in the third quarter of 2020 in favor of expanding the Company’s graphite business has allowed for the investment of an additional $1.6 million during the quarter for product development costs, including pilot plant planning and graphite product testing as part of its Coosa Graphite Project.
General and Administrative Expenses. General and administrative expenses from continuing operations for the three-and-nine-months ended September 30, 2020 increased by $0.5 million from their respective periods in 2019. The increase was due primarily to a reversal of executive bonuses of approximately $0.4 million which lowered costs in 2019.
Net Loss from Continuing Operations. Represents operating activities related primarily to the Company’s graphite business, corporate general and administrative costs and arbitration costs related to the Company’s damages claim against the Republic of Turkey. The increase in net loss of $2.2 million for both the three-and-nine-month periods ended September 30, 2020 compared to the respective prior year periods in 2019 was primarily due to increased graphite product development costs for product testing and pilot plant planning, and increased arbitration costs.
Net Loss from Discontinued Operations. The uranium and lithium businesses have been combined and reported as discontinued operations due to the decision to sell the uranium business and discontinue investment in the lithium business, both actions undertaken in the third quarter of 2020 to orient additional resources to the graphite business. Net loss from discontinued operations was $6.4 million and $8.6 million for the three-and-nine-month periods ended September 30, 2020, respectively. The $5.7 million and $5.5 million increases from the respective prior periods in 2019 were largely due to a $5.2 million impairment charge recorded against uranium property, plant and equipment in the third quarter of 2020 as a result of the terms of sale of the uranium assets and liabilities to enCore Energy Corp.
Cash and Working Capital from Continuing Operations. At September 30, 2020 the Company’s cash balances were $5.5 million and working capital from continuing operations was $2.9 million. The Company’s cash balance at October 31, 2020 was $53.3 million. Management believes the significant treasury balance has mitigated the Company’s capital risk through 2021 as the Company’s 2021 non-discretionary budget, budgeted graphite pilot plant program and the remaining budgeted product development initiatives are now fully funded. The Company is pursuing project financing to support primary funding of the capital expenditures for construction of the commercial plant set to occur in the second half of 2021.
Shares Outstanding. Total shares outstanding are 19,021,859 at November 12, 2020.

Conference Call & Webcast Information

The conference call will be held on Thursday, November 12, 2020 at 11:00 am Eastern time (9:00 am Mountain Time).

DIAL-IN NUMBERS

1-800-319-4610 (US and Canada)

1-604-638-5340 (International)

Conference ID: Westwater Resources Conference Call

Hosting the call will be Christopher M. Jones, President and Chief Executive Officer of Westwater Resources, who will be joined by Jeffrey L. Vigil, Vice President-Finance and Chief Financial Officer, and Dain McCoig, Vice President of Operations. Mr. Jones will present an overview of the Company’s business, including progress on the sale of its uranium business, and an update on the Coosa Graphite Project, including the status of the construction of the pilot plant and the federal government’s recent ruling on graphite. Mr. Vigil will review the financial results and the financial condition of the Company and Mr. McCoig will be available for questions as part of the call.

The conference call and presentation will also be available via a live webcast through the Company’s website, www.WestwaterResources.net. A replay of the call will be available on the Company’s website for a limited time and by phone using the details below:

REPLAY NUMBERS

1-855-669-9658 (U.S. and Canada)

1-412-317-0088 (International)

Replay Access Code 5521

About Westwater Resources

Westwater Resources (NASDAQ: WWR) is focused on developing energy-related materials. The Company’s battery-materials projects include the Coosa Graphite Project — the most advanced natural flake graphite project in the contiguous United States — and the associated Coosa Graphite Deposit located across 41,900 acres (~17,000 hectares) in east-central Alabama. Commencement of pilot plant operations is scheduled for the fourth quarter of 2020, producing ULTRA-PMG^TM, ULTRA-DEXDG^TM and ULTRA-CSPG^TM in quantities that facilitate qualification testing by potential customers. For more information, please visit www.westwaterresources.net.

Cautionary Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “anticipates,” “believes,” “could,” “scheduled,” and other similar words. All statements addressing events or developments that WWR expects or anticipates will occur in the future, including but not limited to the closing of the transaction with enCore Energy Corp., the commencement of operations at the Company’s proposed pilot plant facilities, future production of battery graphite products, and activities involving the Coosa Graphite Project and the Coosa Graphite Deposit. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties include, but are not limited to, (a) the Company’s ability to successfully construct and operate a pilot plant capable of producing battery grade materials in quantities and on schedules consistent with the Coosa Graphite Project business plan; (b) the Company’s ability to raise additional capital in the future including the ability to utilize existing financing facilities; (c) spot price and long-term contract price of graphite and vanadium; (d) risks associated with our operations and the operations of our partners such as Dorfner Anzaplan, including the impact of COVID-19 and its potential impacts to the capital markets; (e) operating conditions at the Company’s projects; (f) government and tribal regulation of the graphite industry and the vanadium industry; (g) world-wide graphite and vanadium supply and demand, including the supply and demand for energy storage batteries; (h) unanticipated geological, processing, regulatory and legal or other problems the Company may encounter in the jurisdictions where the Company operates or intends to operate, including but not limited to Alabama; (i) the ability of the Company to enter into and successfully close acquisitions or other material transactions, including the proposed transaction to sell uranium assets in Texas and New Mexico to enCore Energy; (j) any graphite or vanadium discoveries not being in high-enough concentration to make it economic to extract the minerals; (k) currently pending or new litigation or arbitration; and (l) other factors which are more fully described in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005253/en/

Westwater Resources

Christopher M. Jones, President & CEO

Phone: 303.531.0480

Jeffrey L. Vigil, Vice President Finance & CFO

Phone: 303.531.0481

Email: [email protected]

Product Sales Contact:

Jay Wago, Vice President – Sales and Marketing

Phone: 303.531.0472

Email: [email protected]

Investor Relations

Porter, LeVay & Rose

Michael Porter

Phone: 212.564.4700

Email: [email protected]

KEYWORDS: Australia/Oceania United States Canada North America Australia Europe Germany Nevada Colorado Idaho New Mexico

INDUSTRY KEYWORDS: Communications Other Energy Mining/Minerals Energy Natural Resources Public Relations/Investor Relations

MEDIA:

Logo

November 12, 2020 8:03 am

TrueBlue to Participate in J.P. Morgan Ultimate Services Investor Conference

TrueBlue to Participate in J.P. Morgan Ultimate Services Investor Conference

TACOMA, Wash.–(BUSINESS WIRE)–
TrueBlue (NYSE:TBI) today announced that Chief Executive Officer Patrick Beharelle and Chief Financial Officer Derrek Gafford will be participating in the J.P. Morgan Virtual Ultimate Services Investor Conference on Thursday, Nov. 19, 2019 and will host investor meetings throughout the day.

About TrueBlue

TrueBlue (NYSE: TBI) is a leading provider of specialized workforce solutions that help clients achieve business growth and improve productivity. In 2019, TrueBlue connected approximately 724,000 people with work. Its PeopleReady segment offers on-demand, industrial staffing services, PeopleManagement offers contingent, on-site industrial staffing and commercial driver services, and PeopleScout offers recruitment process outsourcing (RPO) and managed service provider (MSP) solutions to a wide variety of industries. Learn more at www.trueblue.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005331/en/

Derrek Gafford, Executive Vice President and CFO

253-680-8214

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Banking Professional Services Human Resources Finance

MEDIA:

November 12, 2020 8:03 am

Renesas and Altran Team to Deploy First Social Distancing Wristwatch that uses Ultra-Wideband Chipset with Low Rate Pulse

Renesas and Altran Team to Deploy First Social Distancing Wristwatch that uses Ultra-Wideband Chipset with Low Rate Pulse

Collaboration Develops UWB Wearable Platform for Precision Distance Measurement Applications

TOKYO & NEW YORK–(BUSINESS WIRE)–
Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, and Altran, the global leader in engineering and R&D services, and part of the Capgemini Group, today announced that they have co-developed a wearable solution for social distancing based on Ultra-Wideband (UWB) technology. Earlier this year, Renesas announced it had licensed UWB technology from 3db Access AG, a fabless semiconductor company specializing in secure UWB low power chips to augment Renesas microcontrollers (MCUs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005333/en/

The platform’s form factor, a wristwatch, combines the Renesas Synergy^™S128 MCU featuring HMI capacitive touch with licensed secure ranging UWB technology. Unlike other social distancing wearables based on technologies such as Bluetooth^®Low Energy (BLE), Renesas’ UWB chipset with Low Rate Pulse (LRP) can operate on 10X lower power consumption than competing UWB chips and measure distances with an accuracy of 10cm or less – the precision necessary for social distancing applications. The wristwatch’s safe distance is user-configurable; the wearer is alerted by LEDs and haptic feedback when a second device is detected within this range. Renesas will begin sampling the UWB chipset during the second half of 2021.

As co-developer and system integrator, Altran will leverage the UWB-based platform along with other internal assets to develop additional wearable solutions for social distancing as well as related location-based applications for clients across a broad range of markets. The social distancing wristwatch will be showcased in Altran’s innovation lab.

“After months of global pandemic shutdowns, people will want to feel safe when they return to work, school and social settings in close proximity to others. I’m pleased our collaboration with Altran is about responding to the COVID-19 pandemic with the first LRP UWB social distance wristwatch solution,” said Roger Wendelken, Senior Vice President, Head of MCU Business, IoT and Infrastructure Business Unit at Renesas. “Renesas plans to expand to more use cases in the future such as access control, asset tracking and geofencing.”

“This has been a unique and rewarding project, collaborating with Renesas to bring the first LRP UWB-based social distancing wristwatch to market,” said Scott Houghton, President of Altran’s Semiconductor & Electronics, Industrial & Consumer business. “We’re excited to introduce this platform to other markets; its form factor, power efficiency and accuracy make it an excellent fit – in both COVID and non-COVID applications– across our vertical industries.”

About Altran

Altran is the world leader in engineering and R&D services. Altran offers its clients a unique value proposition to meet their transformation and innovation challenges. Altran supports its clients, from concept through industrialization, to develop the products and services of tomorrow and has been working for more than 35 years with major players in many sectors: Automotive, Aeronautics, Space, Defense & Naval, Rail, Infrastructure & Transport, Energy, Industrial & Consumer, Life Sciences, Communications, Semiconductor & Electronics, Software & Internet, Finance & Public Sector. Altran has more than 50,000 employees operating in over 30 countries.

Altran is an integral part of Capgemini, global leader in consulting, digital transformation, technology, and engineering services. The Group is at the forefront of innovation to address the entire breadth of clients’ opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. A responsible and multicultural company of 265,000 people in nearly 50 countries, Capgemini’s purpose is to unleash human energy through technology for an inclusive and sustainable future. With Altran, the Group reported 2019 combined global revenues of €17 billion.

Visit us at altran.com.

About Renesas Electronics Corporation

Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, infrastructure, and IoT applications that help shape a limitless future. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, and YouTube.

(Remarks) Renesas Synergy is a trademark of Renesas Electronics Corporation. Bluetooth is a registered trademark of Bluetooth SIG, Inc. of the United States. All names of products or services mentioned in this press release are trademarks or registered trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005333/en/

Mark Alden

Renesas Electronics Corporation

+ 1-408-546-3402

[email protected]

David Fondiller

Altran

+ 1-917-748-1440

[email protected]

KEYWORDS: United States Japan North America Asia Pacific New York

INDUSTRY KEYWORDS: Semiconductor Hardware Consumer Electronics Technology Software

MEDIA:

Logo

November 12, 2020 8:03 am

TransAct Technologies Announces Appointment of Randall Friedman to Board of Directors

TransAct Technologies Announces Appointment of Randall Friedman to Board of Directors

HAMDEN, Conn.–(BUSINESS WIRE)–
TransAct Technologies Incorporated (Nasdaq: TACT), a global leader in software-driven technology and printing solutions for high-growth markets, today announced the appointment of Randall Friedman to the Board of Directors, effective November 10, 2020. Following the nomination of Mr. Friedman, the Board will expand to six directors from five.

“We are pleased to welcome Randall Friedman to our already talented Board. Mr. Friedman’s extensive knowledge of restaurants and the food service industry and his deep expertise in business-to-business marketing in the restaurant market will be a huge help to our company given how the sales process has changed so dramatically in a Covid-19 environment. No doubt he will provide invaluable support to our BOHA! marketing and sales efforts. Further, Mr. Friedman’s leadership of a number of leading trade journals including Nation’s Restaurant News, Supermarket News, and Chain Store Age, in addition to his experience helping a number of businesses navigate rapid change and disruption, make him a perfect match for TransAct. We could not be more excited to get to work on our massive opportunities,” said Bart Shuldman, Chairman and CEO of TransAct.

Mr. Friedman, age 47, has over a decade of leadership experience in digital innovation and marketing, strategic planning, business acquisitions and divestitures, as well as restructuring and business evolution. Mr. Friedman also brings industry expertise in the food service technology market. For over ten years, Mr. Friedman served in various senior management roles, including President and Chief Executive Officer, at Lebhar-Friedman, Inc., a business-to-business media company where he was responsible for, among other things, sales and marketing, and focused on the food service and retail markets. In addition, Mr. Friedman is the founder of Iaso Health, LLC, an online search tool for on-demand healthcare options. Mr. Friedman is a graduate of Williams College and received his MBA from the Fordham University School of Business.

About TransAct Technologies Incorporated

TransAct Technologies Incorporated is a global leader in developing software-driven technology and printing solutions for high-growth markets including food service, casino and gaming, POS automation, and oil and gas. The Company’s solutions are designed from the ground up based on customer requirements and are sold under the BOHA! ™, AccuDate™, EPICENTRAL^®, Epic^®, Ithaca^® and Printrex^® brands. TransAct has sold over 3.5 million printers and terminals around the world and is committed to providing world-class service, spare parts and accessories to support its installed product base. Through the TransAct Services Group, the Company also provides customers with a complete range of supplies and consumable items both online at http://www.transactsupplies.com and through its direct sales team. TransAct is headquartered in Hamden, CT. For more information, please visit http://www.transact-tech.com or call (203) 859-6800.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005279/en/

Michael Bowen

ICR, Inc.

[email protected]

203-682-8299

Marc P. Griffin

ICR, Inc.

[email protected]

646-277-1290

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Casino/Gaming Other Technology Technology Entertainment Software

MEDIA:

November 12, 2020 8:03 am

Advanced Energy Introduces New SCR Power Controller With Advanced Performance and New Capabilities to Bring Industry 4.0 to Precision Heating Applications

New Thyro-A+ substantially increases control accuracy in the industry’s smallest design footprint to meet the challenges in semiconductor and industrial manufacturing

DENVER–(BUSINESS WIRE)–Advanced Energy Industries, Inc. (Nasdaq: AEIS) – a global leader in highly engineered, precision power conversion, measurement and control solutions – today announced the expansion of its market-leading line of SCR (silicon controlled rectifier) power controllers with its new Thyro-A+ for precision industrial and semiconductor heating applications. Thyro-A+ provides customers with next-generation SCR accuracy and load monitoring, the industry’s smallest design footprint and new digital control capabilities for precision heating, melting, drying and forming applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005280/en/

Advanced Energy’s new Thyro-A+ SCR power controller provides semiconductor and industrial manufacturers with next-generation SCR accuracy and load monitoring, the industry’s smallest design footprint and new digital control capabilities for precision heating, melting, drying and forming applications. Featuring advanced digital capabilities and a digital control interface, Thyro-A+ enables integration with other connected factory software and applications to deliver on the promise of Industry 4.0. (Photo: Business Wire)

Thyro-A+ has a completely redesigned control engine, enabling a 16x increase to measurement sampling rate over the Thyro-A, for enhanced control accuracy, which substantially improves process uniformity and repeatability, reduces energy consumption, and increases process throughput in precision heating applications. It comes with the industry’s smallest design footprint, delivering industry-leading power density. Featuring a new optional LED display for easy commissioning or visualization, Thyro-A+ offers a number of advanced digital capabilities for remote controlling, self-monitoring and a digital control interface for integration with other connected factory software and applications to deliver on the promise of Industry 4.0.

“Building on Advanced Energy’s renowned family of SCR power controllers, the Thyro-A+ is our most advanced SCR, further expanding the range and capabilities of our solutions to meet the heating application requirements of our industrial and semiconductor customers,” said Andreas Breitkopf, director, photonics and PCS products at Advanced Energy. “Among AE’s other SCR power controllers, Thyro-A+ is certified in the Rockwell Encompass Partner program and connects directly with Rockwell Automation Logix PAC systems, providing customers with a straightforward path to fully integrated system designs.”

Thyro-A+ rounds out AE’s Thyro family of power controllers, which includes Thyro-S, Thyro-A eco, Thyro-A and Thyro-PX series. Thyro-A+ has a new powerful controller, which delivers on industry-leading accuracy, load monitoring and control of power for heating elements, resistive loads and transformer loads in a wide range of heating applications. The design provides lightning-fast installation and replacement with “copy-paste” configuration profiles that easily transfer system parameters between multiple SCR power controllers. Customers reduce system installation costs with the most compact SCR footprint available, and a wide variety of fieldbus protocols allow for the most efficient installation possible, allowing for effortless integration into existing enterprise applications for critical thermal processes.

AE will showcase Thyro-A+, along with its other Rockwell Encompass Partner program products, including the recently announced Impac Series 600 pyrometry platform, at the Rockwell Automation Fair, from November 16 to 20, to be held virtually this year.

For detailed product information and technical specifications, visit the Thyro-A+ page on AE’s website and the product data sheet.

About Advanced Energy

Advanced Energy (Nasdaq: AEIS) is a global leader in the design and manufacturing of highly engineered, precision power conversion, measurement and control solutions for mission-critical applications and processes. AE’s power solutions enable customer innovation in complex applications for a wide range of industries including semiconductor equipment, industrial, manufacturing, telecommunications, data center computing and healthcare. With engineering know-how and responsive service and support around the globe, the company builds collaborative partnerships to meet technology advances, propel growth for its customers and innovate the future of power. Advanced Energy has devoted more than three decades to perfecting power for its global customers and is headquartered in Denver, Colorado, USA. For more information, visit www.advancedenergy.com.

Advanced Energy | Precision. Power. Performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005280/en/

Lora Wilson / Valerie Christopherson

Global Results Communications for Advanced Energy Industries, Inc.

[email protected]

+1 949.306.0276

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Semiconductor Consumer Electronics Communications Technology Public Relations/Investor Relations Hardware

MEDIA:

Logo

Photo

November 12, 2020 8:03 am

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November:

Jefferies Virtual London Healthcare Conference

Date: Tuesday, Nov. 17, 2020
Presentation Time: 5:35 p.m. GMT

Stifel 2020 Virtual Healthcare Conference

Date: Tuesday, Nov. 17, 2020
Presentation Time: 10:40 a.m. ET

The conference presentations will be webcast live and may be accessed by visiting Horizon’s website at http://ir.horizontherapeutics.com. A replay of the webcasts will be available for the event.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005233/en/

Investors:

Tina Ventura

Senior Vice President,

Investor Relations

[email protected]

Ruth Venning

Executive Director,

Investor Relations

[email protected]

U.S. Media:

Geoff Curtis

Executive Vice President,

Corporate Affairs & Chief Communications Officer

[email protected]

Ireland Media:

Ray Gordon

Gordon MRM

[email protected]

KEYWORDS: Europe Ireland United States North America Illinois

INDUSTRY KEYWORDS: Medical Supplies Health Medical Devices Other Health Managed Care Pharmaceutical Biotechnology

MEDIA:

Logo